

populations within the geographically constricted Visium data, including SHH-C2, a population located in histologic nodules, the predominant neuronal-differentiated population SHH-C1, and progenitor populations (SHH-B1 and B2). In addition, we were able to visualize clusters not detectable by scRNAseq – a cluster lining nodules with expression of vascular endothelium marker, reticulin and M2-macrophage genes, and a novel DNA-repair cluster. In addition, Visium data permits the spatial constraint of proliferating cells, which is frequently problematic in scRNAseq, as dividing cells cluster independently. The proliferation is highest in the SHH-B2 minor progenitor population, absent in the SHH-C1 major differentiated population, and is moderate in other population including the SHH-C2 nodules. Group 3 and 4 medulloblastoma are more complex but show preliminary corroboration with scRNAseq data. In summary, Visium allows us to map subpopulations identified by scRNAseq to tumor architecture more definitively and rapidly than IHC. These novel insights advance our understanding of medulloblastoma, a critical step in improving treatment options for children with this disease.

MEDB-45. FUNCTIONAL GENOMICS IDENTIFIES EPIGENETIC REGULATORS AS NOVEL THERAPEUTIC TARGETS FOR SONIC HEDGEHOG MEDULLOBLASTOMA

Foteini Tsiami¹, Federica Piccioni², David Root², Prati Bandopadhyay³, Rosalind Segal⁴, Ghazaleh Tabatabai⁵, Daniel Merk⁵; ¹Department of Neurology & Interdisciplinary Neuro-Oncology, Hertie Institute for Clinical Brain Research, University Hospital Tübingen, Eberhard Karls University Tübingen, Tübingen, Germany. ²The Broad Institute of MIT and Harvard, Cambridge, USA. ³Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, USA. ⁴Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, USA. ⁵Department of Neurology & Interdisciplinary Neuro-Oncology, Hertie Institute for Clinical Brain Research, University Hospital Tübingen, Eberhard Karls University Tübingen, Tübingen, Germany

Medulloblastoma (MB) is among the most common malignant childhood brain tumors that comprises a group of four molecularly distinct diseases. A significant proportion of these tumors is characterized by aberrant activation of the canonical sonic hedgehog (SHH) signaling pathway. Although small-molecule inhibitors targeting Smoothened (SMO) have proven a promising treatment approach for SHH-MB subgroup, primary or acquired resistance impedes its clinical efficacy. Therefore, novel targeted approaches are urgently needed to improve therapeutic strategies for this tumor entity. Here, we conducted a genome-wide CRISPR/Cas9 knockout screen in a murine and a human SHH-MB cell line, SMB21 and DAOY, respectively, in order to decipher tumor-specific genetic dependencies. Our data demonstrate that SMB21 cells highly depend on positive regulators of the SHH pathway, such as Smo and Gli1 for their survival, as opposed to DAOY cells, suggesting that the latter does not represent a faithful model of SHH-MB. Members of the epigenetic machinery such as Dnmt1 and Smarca5 scored strongly as SMB21-context specific essentialities. Pharmacologically, we show that DNMT1 inhibition is efficacious at clinically relevant concentrations against SMO inhibitor-sensitive, as well as resistant SHH-MB cell lines, indicating novel therapeutic avenues for SHH-MB. By performing RNA sequencing of SMB21 cells, we identified early and late changes in global gene expression induced by DNMT1 inhibition, including decreased expression of mediators of SHH signaling, such as Gli1 and Gli2. Of note, gene set enrichment analysis revealed that DNMT1 inhibition downregulates top gene sets associated with cell cycle progression, corroborating the screening results that Dnmt1 is essential for SMB21 proliferation. Further global DNA methylation profiling in SMB cells will help to define the molecular basis of sensitivity to DNMT1 inhibitors in SHH-MB. Summarizing, our data highlight the potential of inhibitors targeting epigenetic regulators in SMO inhibitor-sensitive and resistant MB for more efficacious treatment options.

MEDB-46. ONC201 AFFECTS GROUP 3 MEDULLOBLASTOMA GROWTH BY IMPAIRING CANCER STEM CELLS

Luana Abballe¹, Celeste Antonacci², Matteo Giancesello², Chiara Lago², Francesca Nazio¹, Angela Mastronuzzi¹, Giuseppina Catanzaro³, Angela Di Giannatale¹, Luca Tiberi², Franco Locatelli^{1,4}, Evelina Miele¹; ¹Department of Pediatric Hematology/Oncology and Cellular and Gene Therapy, Rome⁰⁰¹⁶⁵, Italy. ²Armenise-Harvard Laboratory of Brain Cancer, Department CIBIO, University of Trento, Via Sommarive⁹, ³⁸¹²³, Trento, Italy. ³Department of Experimental Medicine, Sapienza University of Rome, Viale Regina Elena ³²⁴, ⁰⁰¹⁶¹, Rome, Italy. ⁴Department of Pediatrics, Sapienza University of Rome, Rome, Italy

Cancer stem cells (CSCs) represent a sub-population of cancer cells capable of proliferating and generating heterogeneous cancer cell types. Acquisition of stemness features may represent a strong advantage for

neoplastic cells to promote tumorigenesis and progression, driving resistance to conventional therapy and promoting disease relapse. CSCs have been discovered and isolated in major pediatric brain tumors, including medulloblastoma (MB), the most common solid malignancy in childhood. The unfolded protein response (UPR) represents an adaptation mechanism to metabolic obstacles in CSCs, able to increase tumor aggressiveness. The initial activation of the UPR is cytoprotective but the acute activation led to cell death. We found that UPR is active in MB stem cells (MBSC) and particularly in group 3 (G3). ONC201 is an imipridone compound that activates p53-independent apoptosis causing changes in gene expression similar to those caused by UPR. Here, we aim to test the in vitro efficacy of ONC201 on G3 MBSC. We selected 4 G3 MBSC (D341-Med, D283-Med, Med411, and CHLA-01-Med), for the in vitro study. Cells were chosen for their “fidelity” to the MB subgroup through the analysis of global methylation profiling, were grown in stemness conditions and expressed stemness markers at high levels. We investigated the efficacy of ONC201 treatment on CSC features, by evaluating cell viability, cell death, protein synthesis, self-renewal, and cell cycle. ONC201 treatment on G3 MB cells led to an upregulation of ATF4, a key molecule of the UPR, and the induction was stronger in MB cultured in a “stem-like” medium. Moreover, in the most MBSC analyzed, ONC201 was effective against CSCs whether by reduced cell viability, protein synthesis, and self-renewal. We also observed a trend of increased cell death. Our results suggest that ONC201 is potentially effective in treating G3 MB by compromising the stem cell compartment, and thus deserving further investigations.

MEDB-47. CD4+ T CELLS RESTRICT MEDULLOBLASTOMA GROWTH AND DISSEMINATION

Tanja Eiseemann, Robert Wechsler-Reya; SBP Medical Discovery Institute, La Jolla, CA, USA

The immune system serves as a powerful defense not only against pathogens and parasites but also against neoplastic cells. Emerging immunotherapies that boost the activity of tumor-reactive immune cells or counteract immune suppressive mechanisms have shown promising effects in certain cancer types. However, the success of immunotherapy for brain tumors has been limited, highlighting the need for a better understanding of the immune microenvironment. Our preliminary studies have shown that T cells critically affect tumor growth in mouse models of the pediatric brain tumor medulloblastoma. In particular, depletion of CD4+ T cells results in more aggressive growth of medulloblastoma cells and allows these cells to metastasize to the spinal cord. To test whether CD4+ T cells can recognize and attack tumor cells directly, we generated MHC class II knockout tumors. Surprisingly, depletion of CD4+ cells still enhanced tumor growth and metastasis. These results suggest that CD4+ T cells regulate medulloblastoma growth independently of MHC II on tumor cells. We hypothesized that CD4+ T cell may not directly kill tumor cells but recruit and activate another effector immune cell type that eliminates tumor cells. As CD4+ T cells have a well-studied helper function for CD8+ T cells, we examined whether their anti-tumoral function relies on the activation of cytotoxic CD8+ T cells. The depletion of CD4+ T cells still resulted in advanced growth of MHC class I-deficient, and thus CD8+ T cell resistant, tumor cells indicating that CD4+ T cells counteract tumor growth in a CD8+ T cell-independent manner. Ongoing studies are aimed at elucidating the mechanisms by which CD4+ T cells regulate medulloblastoma growth, including the antigen-presenting cells that activate them and the effector cells responsible for killing tumor cells. These studies will advance our understanding of the immune microenvironment in medulloblastoma and allow us to design more effective therapies.

MEDB-48. INFANT MEDULLOBLASTOMA - SHH SUBTYPE - WITH RESIDUAL DISEASE. TO TREAT OR NOT TO TREAT

Christine Dahl, Sarita Depani, Kriti Hedges, Fernando Aguirregomezcorra, Kristian Aquilina, Owase Jeelani, Olivia Carney, Sniya Sudhakar, Ulrike Loebel, Felice d'Arco, Kshitij Mankad, Darren Hargrave, Mette Jorgensen; Great Ormond Street Hospital for Children, London, United Kingdom

Management of infant medulloblastoma remains a challenge. Front-line chemotherapy can successfully avoid radiation in low-risk infant medulloblastoma. Patients that do relapse can be salvaged long-term with radiotherapy. We report 4 cases of infants with medulloblastoma treated with chemotherapy (HIT2000 protocol) with residual or progressive disease. RESULTS: Four cases of infant medulloblastoma, all MBEN/nodular desmoplastic SHH type B, p53 WT, no MYC / MYCN amplification. CASE 1: 16 month old girl, metastatic lesions in the cerebellum and meningeal enhancement. Germline SUFU mutation. After 3 cycles of chemotherapy MRI showed more enhancement of the residual disease.